Viridian Therapeutics, Inc. (VRDN)
After hours:
| Previous Close | 14.58 |
| Open | 15.08 |
| Bid | 15.35 x 800 |
| Ask | 15.42 x 600 |
| Day's Range | 15.03 - 15.50 |
| 52 Week Range | 10.93 - 28.35 |
| Volume | |
| Avg. Volume | 906,333 |
| Market Cap | 982.866M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.31 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.27 |
Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 03, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company’s common stock to six
Business WireViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
WALTHAM, Mass., April 29, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights.
Business WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
